Which gene does the cholangiocarcinoma targeting drug pemetinib target and how is it used?

Pemetinib, a small molecule kinase inhibitor developed by Incyte Biopharmaceutical Company in the United States, brings new treatment hope to patients with locally advanced or metastatic cholangiocarcinoma. The drug effectively blocks the proliferation signals of cancer cells by specifically inhibiting the activity of fibroblast growth factor receptors (FGFR) 1, 2, 3 and 4, thereby exerting excellent therapeutic effects. Its unique targeted mechanism of action and low side effects enable patients with cholangiocarcinoma to maintain a higher quality of life during treatment.

For patients with cholangiocarcinoma, genetic testing before using pemetinib is a crucial step. Pemetinib is particularly suitable for patients with cholangiocarcinoma who have FGFR2 gene fusions or rearrangements. Because FGFR gene fusions, rearrangements, translocations and amplifications are closely related to the occurrence of various cancers, including cholangiocarcinoma, patients must undergo genetic testing to confirm whether they have FGFR2 gene fusions or rearrangements before using pemetinib. This critical step is essential to ensure that the drug works optimally while keeping it safe for patients.

In terms of medication, patients with cholangiocarcinoma need to strictly follow the doctor’s instructions and the detailed recommendations in the drug instructions. The recommended medication regimen for pemetinib is: 13.5 mg orally per day for 14 days, followed by 7 days off within a 21-day treatment cycle. Patients need to continue treatment until disease progression or intolerable toxicity occurs. When taking, patients should swallow the tablet whole, without chewing or crushing it, with or without food. Doctors will adjust the dosage of medication in a timely manner based on the patient's specific physical condition and tolerance to the medication.

While taking pemetinib, patients should pay close attention to changes in their physical condition and promptly report any discomfort or abnormal reactions to their doctor. This drug may cause a range of side effects, including but not limited to diarrhea, nausea, taste change, vomiting, loss of appetite, weight loss, constipation, joint pain, painful urination, swelling and pain in the limbs or joints, and blurred vision. If patients experience serious side effects, they should seek medical treatment immediately, and a professional doctor will adjust the treatment plan according to the actual situation.

In short, before using pemetinib, patients with cholangiocarcinoma must undergo genetic testing to confirm the presence of FGFR2 gene fusion or rearrangement. At the same time, patients should strictly follow the doctor's instructions and the recommendations on the drug instructions to take the medication to ensure the effectiveness and safety of the treatment. During the treatment process, patients should maintain close communication with their doctors, provide timely feedback on their physical conditions, and jointly respond to possible situations.